Search
Mirikizumab
go.drugbank.com/drugs/DB14910ApprovedInvestigationalMirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. … [L46237,L46257] Mirikizumab is approved in Japan[L46252] and received a positive opinion from the EMA's Committee for Medicinal Products for Human Use in March 2023.
Products: Misuvya 100 mg/1 mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem, 2 ADET, Misuvya 100 mg/1 mL Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem, 6 ADETCalcitriol
go.drugbank.com/drugs/DB00136ApprovedInvestigationalNutraceuticalof classical nuclear receptors (nVDR), where calcitriol acts as a natural ligand [A175615]. … Calcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D<sub>3</sub>, 1,25-dihydroxyvitamin
Categories: Vitamin D and Analogues, Cytochrome P-450 SubstratesSynonyms: 1-alpha-25-Dihydroxyvitamin D3Eptifibatide
go.drugbank.com/drugs/DB00063ApprovedInvestigationalDerived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
Products: INTEGRILIN INYECTABLE 2 MG/ML., INTEGRILIN IV BOLUS INJECTION 2 mg/mlEthosuximide
go.drugbank.com/drugs/DB00593ApprovedInvestigationalAn anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 2-ethyl-2-methylsuccinimide, (±)-2-ethyl-2-methylsuccinimideEculizumab
go.drugbank.com/drugs/DB01257ApprovedInvestigational[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. … Eculizumab is a monoclonal antibody that targets complement protein C5.
Products: Bekemv 300 mg/30 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 ADET, ELİZARİA 300 MG/30 ML İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADETBrivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. … Briviact received FDA approval on February 19, 2016 [L760].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesProducts: BRIVIACT®10 MG, BRIRENTO® 100 MG TABLETASTestosterone cypionate
go.drugbank.com/drugs/DB13943ApprovedInvestigationalTestosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester. … It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: DEPO-TESTOSTERONE STERILE SOLUTION 100 mg/ml, DEPO-TESTOSTERONE STERILE SOLUTION 200 mg/mlLevamisole
go.drugbank.com/drugs/DB00848ApprovedInvestigationalVet approvedWithdrawn[A178123] Interestingly, levamisole has been found as an adulterant in cocaine and can lead to a variety of adverse effects in individuals using this drug.[A178120] … [A178117] It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations[A178123] Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer.
Categories: Heterocyclic Compounds, 1-RingProducts: PVP- LEVAMISOLE POUR-ON SOLUTION 20 %w/v, PARAKS 40 MG/5 ML ŞURUP, 30 MLRavulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigationalRavulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. … [A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis.
Products: Ultomiris 300 mg/3 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (1 adet), ULTOMIRIS ® RAVULIZUMAB 100MG/ML.Digitoxin
go.drugbank.com/drugs/DB01396ApprovedWithdrawnA cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
Categories: Compounds used in a research, industrial, or household setting, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: Digimerck 0,1 mg/ml - Injektionslösung, Digimerck 0,07 mg - Tabletten